Guggenheim Reaffirms “Buy” Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)

Monte Rosa Therapeutics (NASDAQ:GLUE)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a note issued to investors on Tuesday,Benzinga reports. They presently have a $28.00 price target on the stock. Guggenheim’s price objective would indicate a potential upside of 103.34% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company decreased their target price on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. TD Cowen upgraded shares of Monte Rosa Therapeutics to a “strong-buy” rating in a research note on Monday. Wedbush cut their price target on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, August 3rd. Jefferies Financial Group restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Finally, Weiss Ratings cut shares of Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.50.

Monte Rosa Therapeutics Stock Performance

NASDAQ:GLUE opened at $13.77 on Tuesday. The stock’s 50-day simple moving average is $20.04 and its 200 day simple moving average is $18.77. The company has a market cap of $1.17 billion, a P/E ratio of -7.82 and a beta of 1.59. Monte Rosa Therapeutics has a 52-week low of $4.54 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. The company had revenue of $8.97 million during the quarter, compared to the consensus estimate of $12.91 million. As a group, equities analysts predict that Monte Rosa Therapeutics will post -1.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Monte Rosa Therapeutics news, insider Filip Janku sold 30,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $21.42, for a total transaction of $642,600.00. Following the completion of the sale, the insider owned 59,992 shares of the company’s stock, valued at $1,285,028.64. This trade represents a 33.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Anthony M. Manning sold 10,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director directly owned 10,000 shares of the company’s stock, valued at $231,100. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 81,778 shares of company stock valued at $1,768,581. 6.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several large investors have recently modified their holdings of GLUE. Allworth Financial LP bought a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter worth about $30,000. Russell Investments Group Ltd. acquired a new stake in Monte Rosa Therapeutics during the third quarter worth approximately $32,000. Lazard Asset Management LLC lifted its position in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after acquiring an additional 776 shares during the period. Finally, Prudential Financial Inc. bought a new stake in shares of Monte Rosa Therapeutics during the second quarter worth approximately $54,000. 79.96% of the stock is owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.